Paris, Kenneth http://orcid.org/0000-0003-2496-3947
Wall, Luke A.
Article History
Accepted: 31 May 2022
First Online: 1 July 2022
Declarations
:
: Not applicable/no human subjects.
: Not applicable/no human subjects.
: Kenneth Paris MD: Dr. Paris has been a member of advisory boards and a speaker for Takeda Pharmaceuticals regarding the treatment and diagnosis of primary immunodeficiency. He has participated in clinical trials with Takeda regarding immunoglobulin products and with Chiesi Pharmaceuticals regarding enzyme replacement for ADA-SCID. He is also on the Medical Advisory Committee for the Immunoglobulin National Society who provided figures for this manuscript. Luke Wall MD: Dr. Wall has participated in clinical trials with Takeda Pharmaceuticals regarding immunoglobulin products, and with Chiesi Pharmaceuticals regarding enzyme replacement for ADA-SCID.
Free to read: This content has been made available to all.